Tanshinone IIA attenuates atherosclerosis via inhibiting NLRP3 inflammasome activation

Wen, Jiexia; Chang, Yu‐Mei; Huo, Shanshan; Li, Wenyan; Huang, Hongming; Gao, Yuan; Lin, Hongyu; Zhang, Jianlou; Zhang, Yonghong; Zuo, Yuanmei; Cao, Xuebin; Zhong, Fei

doi:10.18632/aging.202202

Cited by 40 publications

(30 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This phenomenon may attribute to the different microenvironment in cells. For example, tanshinone IIA attenuates atherosclerosis by inhibiting NLRP3 inflammasome activation in macrophages (19), while the expression of IL-1β and IL18 was inhibited in HeLa cells after tanshinone II A treatment (11). Briefly, the present study provides evidence to support tanshinone IIA as a potent drug to treat NPC.…”

Section: Discussionsupporting

confidence: 55%

“…Notably, tanshinone IIA exhibits the opposite effect on normal cells and tumor cells, which may attribute to the different microenvironment. For example, tanshinone IIA attenuates atherosclerosis by inhibiting NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in macrophages (19), while the expression of IL-1β and IL18 was inhibited in Hela cells after tanshinone II A treatment (11). Briefly, tanshinone IIA enhanced pyroptosis in HK1 cells.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Tanshinone IIA regulates microRNA‑125b/foxp3/caspase‑1 signaling and inhibits cell viability of nasopharyngeal carcinoma

2021

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a common disease with high prevalence worldwide, affecting hundreds of thousands of patients every year. Although its progress can be inhibited by concurrent chemoradiotherapy and platinum-based agents, there is also a need for novel drugs to treat NPC. The present study identified tanshinone IIA as a potent drug that could suppress the proliferation of HK1 cells by enhancing pyroptosis via regulation of the miR-125b/foxp3/caspase-1 signaling pathway. Firstly, the effects of tanshinone IIA on HK1 cells were assessed and it was confirmed that treatment with tanshinone IIA significantly decreased the proliferation of HK1 cells, with increased activity of caspase-3 and caspase-9. Then, the pyroptosis levels after tanshinone IIA administration were detected. The results showed that tanshinone IIA enhanced pyroptosis in a dose-dependent manner. Furthermore, the mechanism underlying the effects of tanshinone IIA on HK1 cells were explored. It was found that transfection with a microRNA (miR)-125b agomir and a small interfering RNA (si)-foxp3 plasmid reversed the inhibitory effect induced by tanshinone IIA, accompanied by an increase in reactive oxygen species levels and lactate dehydrogenase release, indicating a critical role of miR-125b/foxp3 signaling in pyroptosis in HK1 cells. In conclusion, the present study demonstrates that tanshinone IIA enhances pyroptosis and inhibits the proliferation of HK1 cells by modulating miR-125b/foxp3/caspase-1/GSDMD signaling. It is the first study to reveal the inhibitory effect of tanshinone IIA on HK1 cells and to demonstrate the critical role of miR-125b/foxp3 signaling in mediating these effects, providing robust evidence for the treatment of NPC.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Resultsmentioning

confidence: 99%

Tanshinone IIA regulates microRNA‑125b/foxp3/caspase‑1 signaling and inhibits cell viability of nasopharyngeal carcinoma

2021

View full text Add to dashboard Cite

show abstract

“…Tan et al reported that tanshinone IIA increased cholesterol efflux and reduced lipid accumulation in macrophages, leading to a reduction in the development of aortic atherosclerosis [80]. Wen et al reported that tanshinone IIA inhibited oxidized LDL-induced NLRP3 inflammasome activation in mouse macrophages and ameliorated atherogenesis [81]. These findings indicated that tanshinone IIA possessed the potential activities for anti-inflammation and antiatherosclerosis.…”

Section: Discussionmentioning

confidence: 97%

Tanshinone IIA Downregulates Lipogenic Gene Expression and Attenuates Lipid Accumulation through the Modulation of LXRα/SREBP1 Pathway in HepG2 Cells

et al. 2021

View full text Add to dashboard Cite

Abnormal and excessive accumulation of lipid droplets within hepatic cells is the main feature of steatosis and nonalcoholic fatty liver disease (NAFLD) or metabolic-associated fatty liver disease (MAFLD). Dysregulation of lipogenesis contributes to hepatic steatosis and plays an essential role in the pathological progress of MAFLD. Tanshinone IIA is a bioactive phytochemical isolated from Salvia miltiorrhiza Bunge and exhibits anti-inflammatory, antiatherosclerotic and antihyperlipidemic effects. In this study, we aimed to investigate the lipid-lowering effects of tanshinone IIA on the regulation of lipogenesis, lipid accumulation, and the underlying mechanisms in hepatic cells. We demonstrated that tanshinone IIA can significantly inhibit the gene expression involved in de novo lipogenesis including FASN, ACC1, and SCD1, in HepG2 and Huh 7 cells. Tanshinone IIA could increase phosphorylation of ACC1 protein in HepG2 cells. We further demonstrated that tanshinone IIA also could suppress the fatty-acid-induced lipogenesis and TG accumulation in HepG2 cells. Furthermore, tanshinone IIA markedly downregulated the mRNA and protein expression of SREBP1, an essential transcription factor regulating lipogenesis in hepatic cells. Moreover, we found that tanshinone IIA attenuated liver X receptor α (LXRα)-mediated lipogenic gene expression and lipid droplet accumulation, but did not change the levels of LXRα mRNA or protein in HepG2 cells. The molecular docking data predicted tanshinone IIA binding to the ligand-binding domain of LXRα, which may result in the attenuation of LXRα-induced transcriptional activation. Our findings support the supposition that tanshinone IIA possesses a lipid-modulating effect that suppresses lipogenesis and attenuates lipid accumulation by modulating the LXRα/SREBP1 pathway in hepatic cells. Tanshinone IIA can be potentially used as a supplement or drug for the prevention or treatment of MAFLD.

show abstract

“…Tanshinone ⅡA could decrease oxidized low-density lipoprotein (oxLDL)-induced expression of lectin-like oxidized LDL receptor-1 (LOX-1) and CD36 ( Wen et al, 2020 ). And salvianolic acid B inhibited macrophage uptake of modified LDL in a scavenger receptor CD36–dependent manner ( Bao et al, 2012 ).…”

Section: Targeting Lipid Metabolism With Bioactive Compounds From Tcms With Anti-obesity Effectsmentioning

confidence: 99%

The Anti-Obesity Effect of Traditional Chinese Medicine on Lipid Metabolism

Fan

Liang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

With the improvement of living conditions and the popularity of unhealthy eating and living habits, obesity is becoming a global epidemic. Obesity is now recognized as a disease that not only increases the risk of metabolic diseases such as type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), and cancer but also negatively affects longevity and the quality of life. The traditional Chinese medicines (TCMs) are highly enriched in bioactive compounds and have been used for the treatment of obesity and obesity-related metabolic diseases over a long period of time. In this review, we selected the most commonly used anti-obesity or anti-hyperlipidemia TCMs and, where known, their major bioactive compounds. We then summarized their multi-target molecular mechanisms, specifically focusing on lipid metabolism, including the modulation of lipid absorption, reduction of lipid synthesis, and increase of lipid decomposition and lipid transportation, as well as the regulation of appetite. This review produces a current and comprehensive understanding of integrative and systematic mechanisms for the use of TCMs for anti-obesity. We also advocate taking advantage of TCMs as another therapy for interventions on obesity-related diseases, as well as stressing the fact that more is needed to be done, scientifically, to determine the active compounds and modes of action of the TCMs.

show abstract

Tanshinone IIA attenuates atherosclerosis via inhibiting NLRP3 inflammasome activation

Cited by 40 publications

References 56 publications

Tanshinone IIA regulates microRNA‑125b/foxp3/caspase‑1 signaling and inhibits cell viability of nasopharyngeal carcinoma

Tanshinone IIA regulates microRNA‑125b/foxp3/caspase‑1 signaling and inhibits cell viability of nasopharyngeal carcinoma

Tanshinone IIA Downregulates Lipogenic Gene Expression and Attenuates Lipid Accumulation through the Modulation of LXRα/SREBP1 Pathway in HepG2 Cells

The Anti-Obesity Effect of Traditional Chinese Medicine on Lipid Metabolism

Contact Info

Product

Resources

About